“Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s129. doi:10.25251/skin.7.supp.129.